Jove
Visualize
联系我们

相关概念视频

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evidence for a Potential Context-Dependent Dual Role of Eb Peptide of IGF-1Eb in Cancer Cell Survival and Adaptation to UV Stress.

International journal of molecular sciences·2026
Same author

Finite Element Analysis of Conventional Fixation and 3D-Printed Scaffold Integration for Treating Large Osseous Femoral Defects.

Journal of biomedical materials research. Part B, Applied biomaterials·2025
Same author

The Genetic and Biological Basis of Pseudoarthrosis in Fractures: Current Understanding and Future Directions.

Diseases (Basel, Switzerland)·2025
Same author

Decoding the Role of Insulin-like Growth Factor 1 and Its Isoforms in Breast Cancer.

International journal of molecular sciences·2024
Same author

Colorectal cancer screening: Modalities and adherence.

World journal of gastroenterology·2024
Same author

Anti-PEc: Development of a novel monoclonal antibody against prostate cancer.

British journal of cancer·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 9, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.3K

新兴乳腺癌亚种群:功能异质性超越经典亚型

Amalia Kotsifaki1, Georgia Kalouda1, Efthymios Karalexis1

  • 1Physiology Laboratory, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

International journal of molecular sciences
|December 11, 2025
PubMed
概括

乳腺癌比以前想象的更复杂,发现了新的亚型. 这些新兴的乳腺癌 (BC) 分类提供了更好的预后,并指导了针对性疾病的向治疗.

关键词:
这就是BRCAness的意义.在HER2-低的水平下.乳腺癌的亚型 乳腺癌的亚型克劳丁-低的时间新兴的人口新兴的人口.功能异质性的功能异质性内异质性的异质性精确瘤学 精确瘤学预后生物标志物 预后生物标志物瘤微环境是一个微环境.

更多相关视频

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.8K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K

相关实验视频

Last Updated: Jan 9, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.3K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.8K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K

科学领域:

  • 在瘤学瘤学.
  • 基因组学就是基因组学.
  • 生物标志物 生物标志物

背景情况:

  • 乳腺癌 (BC) 被认为是一种异质性疾病,超过了传统的分类,如光线A / B,HER2丰富和三阴性 (TNBC).
  • 新兴的子群体,如HER2低,克劳丁低,BRCA缺乏 (BRCAness) 和精细的TNBC子群 (例如光线AR,基底类免疫变异) 呈现出新的复杂性.
  • 这些新的分类提供了更好的预后洞察力和治疗途径.

研究的目的:

  • 综合审查新出现的乳腺癌亚型,超越经典的分类学.
  • 在定义这些子组时,整合多原子和液体活检生物标志物的证据.
  • 突出这些生物标志物对向治疗的预测价值和瘤微环境 (TME) 的作用.

主要方法:

  • 从基因组,表观遗传和蛋白质组分析中整合证据.
  • 分析与免疫相关的生物标志物和液体活检数据.
  • 对研究瘤微环境 (TME) 和瘤内异质性的研究进行审查.

主要成果:

  • 新的乳腺癌分类,包括HER2-low,claudin-low,BRCAness和精细的TNBC子集,提供了更大的生物分辨率.
  • 这些新出现的亚型与不同的预后有关,并预测针对性治疗的反应,如抗体-药物合物,PARP抑制剂和免疫检查点抑制剂.
  • 瘤微环境 (TME) 和内异质性显著影响这些新兴乳腺癌实体的生物学和临床行为.

结论:

  • 识别新出现的乳腺癌亚型代表了向动态,生物标志物驱动的精确瘤学转变的范式.
  • 这些在临床上可行的群体使得更好的患者分层和更精细的预后,积极的乳腺癌.
  • 从静态受体模型转向动态,生物标志物驱动的框架对于推进乳腺癌治疗至关重要.